AGC Biologics to manufacture Teikoku Seiyaku's KTP-001
Analysis based on 7 articles · First reported May 26, 2026 · Last updated May 26, 2026
This agreement is expected to positively impact both ADMA Biologics and Teikoku Seiyaku. For ADMA Biologics, it reinforces its position as a leading CDMO with a global network, potentially attracting more clients. For Teikoku Seiyaku, securing manufacturing for KTP-001 is a critical step towards bringing a new therapy to market, which could lead to future revenue streams.
ADMA Biologics has been selected by Teikoku Seiyaku Co., Ltd. to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7) drug substance aimed at treating lumbar disc herniation. The partnership will leverage ADMA Biologics' global network, with initial cell bank creation at its Heidelberg, Germany site, followed by process development and GMP manufacturing at its Chiba, Japan facility to support clinical trials. This collaboration highlights ADMA Biologics' unique position as a CDMO with microbial manufacturing capabilities across Asia, North America, and Europe, offering supply chain security and flexibility to drug developers. Executives from both companies expressed enthusiasm for the project, emphasizing the potential for a new, less invasive therapy for patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard